Combined RNA interference and gene therapy for Charcot-Marie-Tooth type 2A disease

Researchers from centers in Milan, Italy, suggest that adopting a dual approach to therapy for Charcot-Marie-Tooth type 2A (CMT2A) disease is effective in two model systems and may lead to an effective treatment for patients.